Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Comparative Analysis of Radioactive Iodine Versus Thyroidectomy for Definitive Treatment of Graves’ Disease
source: Surgery
year: 2017
authors: Wu VT, Lorenzen AW, Beck AC, Reid VJ, Sugg SL, Howe JR, Pollard JH, Lal G, Weigel RJ
summary/abstract:Background:
Management of Graves disease includes antithyroid drugs, 131I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
Methods:
This was a retrospective review of patients undergoing 131I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases.
Results:
131I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than 131I therapy (17.1% vs 9.2%, P = .026). The success rate of the first 131I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with 131I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. 131I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than 131I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients.
Conclusion:
A higher proportion of pediatric Graves disease patients underwent thyroidectomy than 131I therapy. Rapid turnover suggested more effective initial management with operation than 131I therapy. Although transient operative complications were high, 131I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
DOI: 10.1016/j.surg.2016.06.066
read more full text
myBinderRelated Content
-
American Society of Ophthalmic Plastic & Reconstructive SurgeryThe American Society of Ophthalmic Plast...
-
New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durabil...Horizon Therapeutics plc announced posit...
-
Subclinical Hypothyroidism After 131I-Treatment of Graves’ Disease: A Risk Factor for Depression?Objectives: Although it is well accepte...
-
Erin M. Shriver, MD, FACSErin M. Shriver is a Clinical Professor ...
-
Drug Versus Radioactive Treatment of Graves’ Disease – Metabolic OutcomesBackground: Weight gain is a common com...
-
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
-
Remission After Potassium Iodide Therapy in Patients With Graves’ Hyperthyroidism Exhibiting Thionamide-Associ...Context: Thionamides have various side ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google